Pietro Sollena

12PUBLICATIONS
78CO-AUTHORS
AllergyPhysical chemistry not elsewhere classifiedMolecular targetsMajor global burdens of diseaseMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

|Nov 27, 2024
Uncommon Presentation of Pityriasis Rubra Pilaris of the Scalp: Clinical, Trichoscopic, and Histopathologic Features and Review of the Literature.

Michela Starace, Stephano Cedirian, Federico Quadrelli

|Nov 03, 2024
LC-OCT for early diagnosis and characterization of dermatologic adverse events to oncologic drugs and correlation to histopathology.

Pietro Sollena, Marisa Salvi, Marica Marraffa

|Oct 26, 2024
Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.

Z Apalla, A Freites-Martinez, K Grafanaki

|Jan 22, 2024
Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors.

Eleonora De Luca, Pietro Sollena, Lucia Di Nardo

|Dec 15, 2021
European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.

Z Apalla, V Nikolaou, D Fattore

Pageof 2

Frequent Collaborators

3 joint publications

Michela Starace

3 joint publications

Zoe Apalla

3 joint publications

Vasiliki Nikolaou

3 joint publications

Davide Fattore